If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Chitosan is produced commercially by deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans (such as crabs and shrimp) and cell walls of fungi. A common method for obtaining chitosan is the deacetylation of chitin using sodium hydroxide in excess as a reagent and water as a solvent. The reaction follows first-order kinetics though it occurs in two steps; the activation energy barrier for the first stage is estimated at 48.8 kJ·mol−1 at 25–120 °C (77–248 °F) and is higher than the barrier to the second stage.
Brenner has developed targeted, quantitative analysis of the NAD+ metabolome and made fundamental contributions to NAD metabolism including discovery of nicotinic acid riboside-dependent NAD synthesis, elucidating the mechanism of synthesis of nicotinic acid adenine dinucleotide phosphate, and discovering multiple conditions in which NAD metabolism is dysregulated in disease. Brenner is active in translating NR technologies to treat and prevent human conditions that disturb the NAD system including cancer diabetic and chemotherapeutic peripheral neuropathy, heart failure, central brain injury, inflammation, mitochondrial myopathy pellagra, and infections such as coronavirus infection Brenner's work included the first human trial of NR in 2016, which demonstrated safe oral availability as an NAD+ precursor, thereby creating the foundational intellectual property for the NAD boosting industry. Though Brenner was the first to show that NR increases SIR2 activity, improves gene silencing, and can extend yeast lifespan, his work has not emphasized sirtuins or nonspecific anti-aging claims and instead emphasizes how NR repairs inflammatory conditions and metabolic stresses that dysregulate NAD+ and NADPH.
As the moral authority of Barre's government was gradually eroded, many Somalis became disillusioned with life under military rule. By the mid-1980s, resistance movements supported by Ethiopia's communist Derg administration had sprung up across the country. Barre responded by ordering punitive measures against those he perceived as locally supporting the guerrillas, especially in the northern regions. The clampdown included bombing of cities, with the northwestern administrative centre of Hargeisa, a Somali National Movement (SNM) stronghold, among the targeted areas in 1988. The clampdown initiated by Barre's government extended its reach beyond the initial bombings in the north to encompass various regions across the country. This reproduction of aggressive strategies aimed at stifling dissent and retaining authority over the populace was a hallmark of the government's repressive actions in the South. One of the most notable instances occurred in 1991, when Barre's regime initiated a ruthless aerial assault that led to the deaths of numerous individuals in the town of Beledwene, situated in southern Somalia. Another notable instance of Barre's repressive policies occurred in the city of Baidoa, which earned the nickname 'the city of death' due to the events that unfolded there during the famine and civil war. Hundreds of thousands of individuals lost their lives as a consequence of governmental strategies specifically aimed at the Rahanweyn community residing in these areas.
Sources: en.wikipedia.org
Inquiries sent to the IDF regarding the experiences of these health care workers received a statement from a spokesperson that did not directly confirm whether investigations into the shootings of preteen children had been conducted or if any soldiers faced disciplinary action for firing at them. In response to claims alleging that the report was based on "fabricated evidence", The New York Times issued a statement defending the integrity of the piece, emphasizing that it had undergone rigorous editing and verification, including consultations with experts and the use of supporting photographs, which they deemed "too horrific for publication." De Volkskrant interviewed 17 doctors who had volunteered during the Gaza war. Fifteen of them reported seeing children with "a single gunshot wound to the head and/or chest." These doctors reported seeing 114 children injured this way. In response, former Commander of the Royal Netherlands Army Mart de Kruif told the paper, "If you're seeing a high number of gunshot wounds to the chest area and the head, that’s not collateral damage – that’s deliberate targeting." In one documented case, a girl was reportedly shot and killed while in her mother's arms. In June 2026, a 94-page report by the UN Independent International Commission of Inquiry on the Occupied Palestinian Territory concluded there were reasonable grounds to determine that Israeli forces directly targeted children in Gaza using snipers and quadcopter drones.
He concluded that perineurial cysts should be considered in patients with gradually worsening sacral nerve symptoms when imaging or surgery fails to reveal a herniated disc. In 1953, Dr. Isadore Tarlov published a monograph titled Sacral Nerve-Root Cysts: Another Cause of the Sciatic or Cauda Equina Syndrome, which compiled his anatomical, histological, and clinical research on perineurial cysts. The book combined scientific analysis with case studies to illustrate the symptoms, surgical techniques, and outcomes associated with sacral cysts. In Chapter 8, titled "Clinical Significance", Tarlov presented ten patient case reports documented between 1948 and 1952, four of which involved surgeries he personally performed. The remaining cases were managed by other surgeons using various techniques. Reported symptoms included pain, paresthesia, numbness (e.g., of the penis, thigh, buttocks, rectum, or vagina), urinary incontinence, and foot weakness with absent ankle reflex. Complete surgical removal of isolated cysts often led to full recovery, while patients with multiple cysts saw more limited improvement due to conservative surgical approaches. He concluded the monograph by urging increased clinical awareness of these lesions, stating that perineurial cysts may be a surgically treatable cause of sciatic and sacrococcygeal syndromes.
The Kingdom of Kucha, the most populous oasis in the Tarim Basin, occupied a strategic position on the Northern Silk Road, which brought it prosperity, and made it a wealthy center of trade and culture. Kucha was part of the Silk Road economy, and was in contact with the rest of Central Asia, including Sogdiana and Bactria, and thus also with the cultures of India, Iran, and coastal areas of China. Early visitors are known, such as Maes Titianus. Since the 2nd century CE, under the auspices of the Han dynasty and the Kushan Empire, numerous great Buddhist missionaries passed through the Tarim Basin on their way to China, such as the Parthian An Shigao, the Yuezhis Lokaksema and Zhi Qian, or the Indian Chu Sho-fu (竺朔佛). Culture flourished, and Indian Sanskrit scriptures were being translated by the Kuchean monk and translator Kumarajiva (344–413 CE), himself the son of a Buddhist man from Kashmir and a Kuchean princess, sister of the King. The 1st Style, sometimes called "First Indo-Iranian style" to denote influences from India and Central Asia, covers a period from 300 to 500 CE, and is characterized by Gandharan themes and orange and green hues, having a strong flavour of India: female dancers and musicians are often naked or half-naked with full breasts. The art of these paintings is quite refined, and forms the "Classical" period of the art of Kizil: the shades are delicate, the lines are fine and elegant, the colors blend progressively to give a sense of texture and volume.
Sources: en.wikipedia.org
On 15 May 2015, the FDA issued a warning that certain SGLT2 diabetes drugs, including canagliflozin, may lead to ketoacidosis, a condition where the body produces higher levels of ketone bodies. The FDA is continuing to investigate the issue, and cautions that patients should not stop taking canagliflozin without first talking to their doctor. On 10 September 2015, the FDA issued a drug safety communication for canagliflozin to address risks for bone fracture and decreased bone density. A label warning for fractures was already included in the Adverse Reactions section; however, the FDA made the addition to the Warnings and Precautions section to reflect new information from a placebo study. They advised that health care professionals should consider fracture risk factors before prescribing canagliflozin, and patients should disclose any bone fracture risk factors to their doctors, but that patients should not stop taking the medication without first talking to their doctor. On 4 December 2015, the FDA issued another safety communication for SGLT2 inhibitors, indicating that it would require new warnings to be added to the canagliflozin label about elevated blood acid levels and urinary tract infections. In June 2016, the FDA strengthened the warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).
In humans the main gluconeogenic precursors are lactate, glycerol (which is a part of the triglyceride molecule), alanine and glutamine. Altogether, they account for over 90% of the overall gluconeogenesis. Other glucogenic amino acids and all citric acid cycle intermediates (through conversion to oxaloacetate) can also function as substrates for gluconeogenesis. Generally, human consumption of gluconeogenic substrates in food does not result in increased gluconeogenesis. In ruminants, propionate is the principal gluconeogenic substrate. In nonruminants, including human beings, propionate arises from the β-oxidation of odd-chain and branched-chain fatty acids, and is a (relatively minor) substrate for gluconeogenesis. Lactate is transported back to the liver where it is converted into pyruvate by the Cori cycle using the enzyme lactate dehydrogenase. Pyruvate, the first designated substrate of the gluconeogenic pathway, can then be used to generate glucose. Transamination or deamination of amino acids facilitates entering of their carbon skeleton into the cycle directly (as pyruvate or oxaloacetate), or indirectly via the citric acid cycle. The contribution of Cori cycle lactate to overall glucose production increases with fasting duration. Specifically, after 12, 20, and 40 hours of fasting by human volunteers, the contribution of Cori cycle lactate to gluconeogenesis was 41%, 71%, and 92%, respectively. Whether even-chain fatty acids can be converted into glucose in animals has been a longstanding question in biochemistry.
In Euclidean geometry, a tangential quadrilateral (sometimes just tangent quadrilateral) or circumscribed quadrilateral is a convex quadrilateral whose sides all can be tangent to a single circle within the quadrilateral. This circle is called the incircle of the quadrilateral or its inscribed circle, its center is the incenter and its radius is called the inradius. Since these quadrilaterals can be drawn surrounding or circumscribing their incircles, they have also been called circumscribable quadrilaterals, circumscribing quadrilaterals, and circumscriptible quadrilaterals. Tangential quadrilaterals are a special case of tangential polygons. Other less frequently used names for this class of quadrilaterals are inscriptable quadrilateral, inscriptible quadrilateral, inscribable quadrilateral, circumcyclic quadrilateral, and co-cyclic quadrilateral. Due to the risk of confusion with a quadrilateral that has a circumcircle, which is called a cyclic quadrilateral or inscribed quadrilateral, it is preferable not to use any of the last five names. All triangles can have an incircle, but not all quadrilaterals do. An example of a quadrilateral that cannot be tangential is a non-square rectangle. The section characterizations below states what necessary and sufficient conditions a quadrilateral must satisfy to be able to have an incircle.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.